SPI 339

Drug Profile

SPI 339

Alternative Names: NEO 339

Latest Information Update: 02 Jul 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spectrum Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Mild cognitive impairment

Most Recent Events

  • 02 Jul 2003 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
  • 02 Jul 2003 Discontinued - Preclinical for Mild cognitive impairment in USA (unspecified route)
  • 02 Jul 2003 SPI 339 is available for licensing (http://www.spectrumpharm.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top